Reconstructing analgesic trials: reasons for following the lead of oncologists.
Changes in drug trial designs in oncology, which involve targeted therapies and well genotyped cancers have important implications to the present trial designs used for analgesic development. Pain phenotypes influence analgesic responses. Analgesics can now be targeted to pain phenotypes. IMMPACT strategies should be modified using pharmacokinetic-pharmacodynamics and phase II-III trial designs commonly used in oncology. Modifying analgesic trial designs will facilitate the development of targeted analgesics and improve the 'signal-to-noise' ratio over present analgesic trial strategies, which are largely based on pain severity and changes in pain intensity over time.